Publicaciones en colaboración con investigadores/as de University of British Columbia (18)

2022

  1. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

    Respiratory Medicine, Vol. 200

2021

  1. Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism

    American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

    Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942

  3. Further delineation of the clinical spectrum of KAT6B disorders and allelic series of pathogenic variants

    Genetics in Medicine, Vol. 22, Núm. 8, pp. 1338-1347

  4. Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"

    Journal of Clinical Endocrinology and Metabolism

  5. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling

    Biological Psychiatry, Vol. 87, Núm. 2, pp. 100-112

  6. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Bone, Vol. 130

2019

  1. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis

    Bone, Vol. 120, pp. 1-8

  2. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Archives of Osteoporosis, Vol. 14, Núm. 1

2018

  1. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

    Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794

  2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

    The Lancet, Vol. 391, Núm. 10117, pp. 230-240

  3. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course 06 Biological Sciences 0604 Genetics 11 Medical and Health Sciences 1109 Neurosciences

    Journal of Neuroinflammation, Vol. 15, Núm. 1

  4. Teriparatide vs risedronate for osteoporosis – Authors' reply

    The Lancet

2017

  1. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  2. Clinical delineation of the PACS1-related syndrome-Report on 19 patients

    American Journal of Medical Genetics, Part A, Vol. 170, Núm. 3, pp. 670-675

2013

  1. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649